BAKER BROS. ADVISORS LP Q4 2021 Filing
Filed February 14, 2022
Portfolio Value
$20.6B
Holdings
121
Report Date
Q4 2021
Filing Type
13F-HR
All Holdings (121 positions)
| # | Stock | Shares | Value | % Portfolio | Type |
|---|---|---|---|---|---|
| 101 | CABACabaletta Bio, Inc. | 662,063 | $2.5B | 12.21% | |
| 102 | AKROAkero Therapeutics, Inc. | 118,378 | $2.5B | 12.18% | |
| 103 | —Vincerx Pharma, Inc. | 241,379 | $2.5B | 11.97% | |
| 104 | BDQMAlbireo Pharma, Inc. | 104,521 | $2.4B | 11.84% | |
| 105 | SNDXSyndax Pharmaceuticals, Inc. | 110,729 | $2.4B | 11.79% | |
| 106 | KZRKezar Life Sciences, Inc. | 139,676 | $2.3B | 11.36% | |
| 107 | BNRBurning Rock Biotech Limited | 209,131 | $2.0B | 9.70% | |
| 108 | LPTXEURLeap Therapeutics, Inc. | 559,705 | $1.8B | 8.82% | |
| 109 | HOOKGBPHOOKIPA Pharma Inc. | 700,481 | $1.6B | 7.94% | |
| 110 | —Gamida Cell Ltd. | 610,626 | $1.6B | 7.55% | |
| 111 | SERASera Prognostics, Inc. | 201,562 | $1.4B | 6.74% | |
| 112 | —NexImmune, Inc. | 294,117 | $1.4B | 6.60% | |
| 113 | TARAProtara Therapeutics, Inc. | 199,671 | $1.3B | 6.56% | |
| 114 | OYSTOyster Point Pharma, Inc. | 61,424 | $1.1B | 5.46% | |
| 115 | —LogicBio Therapeutics, Inc. | 451,478 | $1.0B | 5.07% | |
| 116 | FHTXFoghorn Therapeutics Inc. | 45,027 | $1.0B | 5.01% | |
| 117 | —Evofem Biosciences, Inc. | 2,697,110 | $1.0B | 4.93% | |
| 118 | SRZNWSurrozen, Inc. | 833,333 | $958.0M | 4.66% | |
| 119 | PASGPassage Bio, Inc. | 117,161 | $744.0M | 3.62% | |
| 120 | INZYInozyme Pharma, Inc. | 106,999 | $730.0M | 3.55% | |
| 121 | —Bellicum Pharmaceuticals, Inc. | 249,123 | $371.0M | 1.81% |
PreviousPage 2 of 2